Linde vs Valhi
LIN and VHI side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LIN and VHI compare
Linde is the larger company, worth 504 times as much as Valhi ($240B against $477M).
Linde grew revenue faster over the last twelve months (8.2% versus 3.4% for Valhi).
Linde keeps more of each dollar of sales as profit, with a net margin of 19.3% compared with −2.4% at Valhi.
Both pay dividends: Linde yields 1.2% and Valhi 1.9%.
Linde scores higher on the StockData Score (15 against 7 for Valhi), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LIN | VHI |
|---|---|---|
| Size and price | ||
| Market cap | $240B | $477M |
| Share price | $523.46 | $16.85 |
| Change, 1 year | 22.1% | 30.2% |
| Change, 5 years | 63.3% | −36.9% |
| Beta (5Y) | −0.08 | 0.06 |
| Employees | 65K | 549 |
| StockData Score | ||
| Total score | 15 (better) | 7 |
| Valuation score | 0 | 3 (better) |
| Growth score | 3 (better) | 0 |
| Performance score | 5 (better) | 0 |
| Health score | 3 (better) | 2 |
| Dividend score | 4 (better) | 2 |
| Valuation | ||
| P/E | 34.8× | – |
| P/S | 6.6× | 0.2× (better) |
| P/B | 6.1× | 0.5× (better) |
| EV/EBITDA | 20.4× | 8.2× (better) |
| P/FCF | 47.3× | 7.6× (better) |
| PEG | 1.65 | – |
| FCF yield | 2.1% | 13.1% (better) |
| Fair value | $386.50 | $43.97 |
| Margin of safety | −35.4% | 61.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 8.2% (better) | 3.4% |
| Revenue growth, 5Y average | 4.5% (better) | 2.3% |
| Net income growth (TTM) | −1.2% (better) | −152% |
| EPS growth (TTM) | 0.87% | – |
| EPS growth, 5Y average | 25.4% | – |
| Profitability | ||
| Gross margin | 47.9% (better) | 14.7% |
| Operating margin | 25.3% (better) | 3.6% |
| Net margin | 19.3% (better) | −2.4% |
| FCF margin | 14.0% (better) | 2.9% |
| Return on equity | 18.0% (better) | −4.8% |
| Return on invested capital | 11.5% (better) | 4.2% |
| Financial health | ||
| Debt / equity | 0.68 | 0.56 (better) |
| Net debt / EBITDA | 1.75 (better) | 2.56 |
| Interest coverage | 35.5× (better) | 1.3× |
| Current ratio | 0.86 | 3.37 (better) |
| Altman Z-score | 4.10 (better) | 1.87 |
| Piotroski F-score | 7 (better) | 3 |
| Dividends and buybacks | ||
| Dividend yield | 1.2% | 1.9% (better) |
| Payout ratio | 41.6% | – |
| Years of dividend growth | 9 (better) | 0 |
| Dividend growth, 5Y average | 9.3% (better) | −7.8% |
| Buyback yield | 1.7% | – |
| Shareholder yield | 2.9% (better) | 1.9% |
| Ownership | ||
| Held by institutions | 85.7% | 4.2% |
| Held by insiders | 0.20% | 0.26% |
| Insider net buying, 12 months | −$62.0M | – |
| Superinvestors holding | 6 | – |
| Short interest, % of float | 1.5% | 0.21% |
Go deeper
- LIN stock overview
- LIN income statement
- LIN valuation and score
- VHI stock overview
- VHI income statement
- VHI valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.